Glaxosmithkline Biologicals Sa

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Cira Daniela Rinaudo

Guido Grandi

Domenico Maione

Immaculada Margarit Y Ros

Francesco Berti

John Telford

Roberta Cozzi

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 areantigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.

Carrier molecule for antigens

The invention provides proteins and compositions for the treatment and prevention of(Group B; GBS).

Immunogenic proteins and compositions

[object Object]

The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group Bserotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

Growing community of inventors

Castelnuovo Berardenga, Italy

Cira Daniela Rinaudo